Congress Program

Saturday, March 28 Salón Bustillo

5:00 – 6:30 PM

Registration

6:30 – 9:00 PM

Welcome Evening Event Sponsored

Sponsored by David Almeida · Location: Ballrooms

6:30 – 7:30 PM — Cocktail Reception Followed by Dinner
7:30 – 8:15 PM — Paulo Stanga, Victor Gonzalez

Surgical Technique and Pearls for Subretinal Drug Delivery
Panelist: Mario Saravia, Magno Ferreira, Jans Fromow

8:15 – 9:00 PM — Sponsor Talks: Ocugen, 4DMT, Optos, Genentech, Bausch & Lomb, Kodiak, Regeneron, Eyepoint, Adverum
8:55 PM — Wrap Up

Sunday, March 29 Salón Tronador

6:00 – 7:30 AM	Registration
6:00 – 7:45 AM	Breakfast
8:00 – 8:10 AM	Opening Remarks Victor H. Gonzalez · Michael Singer · Mario Saravia
8:10 – 8:25 AM	Introduction of Americas Research Alliance Victor Gonzalez · Michael Singer Mission, Vision
8:25 – 9:30 AM	Introduction of LATAM Investigators / Experience — Mexico - Humberto Ruiz Garcia — Brazil - Jorge Rocha & Fernando Penha — Colombia - Francisco Rodriguez— Peru - Jose Antonio Roca — Argentina - Carlos Zeolite
10:00 – 10:35 AM	Clinical Trials Addressing Dry AMD #1 Moderator: Victor Gonzalez · Panelists: Lawrence Singerman, Antonio Marcelo Casella, Jorge Rocha 10:00 – 10:08 AM — Introduction of Angioplasty for Dry AMD (Philip Rosenfeld) 10:09 – 10:17 AM — Balloon Angioplasty of the Ophthalmic Artery in AMD: Rationale and Results of a Feasibility Study (Mario Saravia) 10:17 – 10:26 AM — Photobiomodulation Therapy: Noninvasive Hope for Retinal Disease (Victor Gonzalez) 10:27 – 10:35 AM — LATAM Impact Discussion
10:35 – 11:05 AM	Coffee Break
11:05 AM – 12:05 PM	Bringing New Treatments and Clinical Trials to LATAM Market: Addressing the Critical Hurdles Moderator: Silvia Zieher · Panelists: Victor H. Gonzalez, Michael Singer, Carlos Zeolite, Joaquin Baffaluy 11:05 – 11:25 AM — Silvia Zieher, Ivana Etcheverry, Celso Arabeti, Maria Julia Cremona 11:25 – 11:35 AM — Jans Fromow Guerra 11:36 – 11:46 AM — Arthur Furlan 11:47 – 12:07 PM — FDA Perspective on Clinical Trials in LATAM (Wiley Chambers)
12:08 – 12:47 PM	Clinical Trials Addressing Dry AMD #2 Moderator: Victor Gonzalez · Panelists: Larry Singerman, Francisco Rodriguez, Jorge Rocha, Paulo Zantut 12:08 – 12:16 PM — Targeting Retinal Bioenergetics in Dry AMD: Why Earlier Treatment with Elamipretide Matters (Victor Gonzalez) 12:17 – 12:25 PM — Structure/Function Relationships in Advanced Dry AMD: Learnings from the Archer Study of ANX007 (David Boyer) 12:26 – 12:34 PM — Long-Term 5-year Outcomes Of Pegcetacoplan Treatment for GA Secondary to AMD from Oaks, Derby and Gale. (Lawrence Singerman) 12:34 – 12:42 PM — AI in GA: Learnings From the Pegcetacoplan Clinical Program. (Lawrence Singerman) 12:43 – 12:47 PM — LATAM Impact Discussion
12:48 – 1:35 PM	Lunch Symposium Sponsored Sponsored by 4DMT Panelists: Carlos Zeolite, David Boyer & Andre Vieira Gomez 1:05 – 1:35 PM — 52-Week Efficacy and Safety Results from the PRISM Phase 2b Cohort Evaluating 4D-150 Gene Therapy in Adults with nAMD (Michael Singer) Interim Phase 2 Results from the SPECTRA Trial Evaluating 4D-150 Gene Therapy in Adults with DME (Victor Gonzalez)
1:40 – 2:22 PM	Tyrosine Kinase Inhibitors in Clinical Trials Moderator: David Boyer · Panelists: Francisco Rodriguez, Jorge Rocha, Claudia Acosta, Michael Singer 1:40 – 1:48 PM — Sub-cutaneous Delivery of Migaldendranib: 24 Week Results of a Phase 2 Study in DME and AMD (David Boyer) 1:49 – 1:57 PM — Suprachoroidal CLS-AX for nAMD: Phase 3 Program Update (Michael Singer) 1:58 – 2:05 PM — Sustained-Release DURAVYU: Update on Clinical Trials in nAMD (Victor Gonzalez) 2:06 – 2:13 PM — DURAVYU: Results from Phase 2 VERONA Trial for DME (Victor Gonzalez) 2:14 – 2:22 PM — LATAM Impact Discussion
2:21 – 3:02 PM	Clinical Trials Investigating Therapies with Novel Mechanisms of Action #1 Moderator: Michael Singer 2:21 – 2:29 PM — Long-Lasting Vision: Anchored Bi-functional Anti-VEGFs. (David Boyer) 2:30 – 2:38 PM — Visual and Anatomical Improvements Over 12 Weeks with OCS-01 Eye Drops in Patients with Diabetic Macular Edema from the Diamond-Stage 1 Trial, (Leticia Cinca) 2:39 – 2:47 PM — ANXV for the Treatment of RVO: A Potential Disease Modifying MOA (Michael Singer) 2:48 – 2:56 PM — OLN324: A Clinical-stage, Small-format, Higher-potency, High Molar Dose Bispecific VEGF/Ang-2 (Michael Singer) Inhibitor. 2:57 – 3:02 PM — LATAM Impact Discussion
3:03 – 3:23 PM	Insights from CRO Leadership in Retina: Key Factors for Successful Clinical Trial Execution Moderator: Paulo Stanga · Panelists: Brad Doerschuk, Silvia Zieher, Arthur Furlan, Celso Arabetti
3:24 – 4:00 PM	Clinical Trials in Inherited Retinal Diseases Moderator: Paulo Stanga · Panelists: Mario Saravia, Victor Gonzalez, Joaquin Bafalluy, Fabiana Arzuaga 3:24 – 3:39 PM — Model IRD Registry (Marcela Ciccioli) 3:39 – 3:46 PM — Novel Modifier Gene Therapy: The Future of Inherited Retinal Diseases, The Guardian Phase 1 Stargardts Study. (Victor Gonzalez) 3:47 – 3:52 PM — 126-week Efficacy, Safety and Visual Acuity Outcomes of MCO-010 for Retinitis Pigmentosa (Victor Gonzalez) 3:53 – 3:58 PM — Subretinal Gene Therapy laru-zova (AGTC-501) for XLRP: Phase 2 DAWN Preliminary Month 6+ Results (Paulo Stanga) 3:58 – 4:05 PM — Study of AR-14034 in Participants with nAMD (NOVA-1) (David Almeida)
4:06 – 4:41 PM	Artificial Intelligence in Clinical Development and Clinical Trials Moderator: Michael Singer · Panelists: David Almeida, Victor Gonzalez, Paulo Stanga 4:16 – 4:20 PM — AI-Based Retinal Imaging Analysis for Clinical Trial Recruitment 4:21 – 4:25 PM — AI Powered Site Selection and Risk Assessment Modeling for Clinical Trials (Brad Doerschuk) 4:26 – 4:30 PM — Leveraging Real-World Evidence and AI to Revolutionize Trials (Victor Gonzalez) 4:31 – 4:36 PM — CTS and Importance of Fully Digital Clinical Sites (Valentin Saravia) 4:36 – 4:41 PM — LATAM Discussion
4:42 – 5:10 PM	Clinical Trials Utilizing Gene Therapy to Treat Common Retinal Diseases Moderator: Michael Singer · Panelists: Paulo Stanga 4:43 – 4:50 PM — Ixo-vec Intravitreal Gene Therapy for Neovascular AMD: Safety and Efficacy Results from the LUNA Trial. (Michael Singer) 4:51 – 4:59 PM — Optos Wide Angle Imaging for Clinical Research Trials. (Paulo Stanga) 5:00 – 5:10 PM — KRIYA-825: A Novel Suprachoroidally Administered Gene Therapy Expressing a Complement C3 and C5 Activity Inhibiting Fusion Protein for the Treatment of GA (David Almeida)
5:11 – 6:09 PM	Latest Updates on Faricimab and Aflibercept 8mg Moderator: Victor Gonzalez · Panelists: Carlos Zeolite, Jans Fromow Guerra, Michael Singer, Laurentino Biccas 5:11 – 5:18 PM — Treatment Response and Safety of Faricimab in Underrepresented Patients with DME: Year 1 TopLine Results from the Phase 4 ELEVATUM Study (Joseph Coney) 5:19 – 5:26 PM — Four-Year Outcomes of Faricimab in DME: Results From the RHONE-X Long-Term Extension Trial (Jans Fromow Guerra) 5:27 – 5:34 PM — Two-Year Real-World Clinical Outcomes in Patients With Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration Treated with Faricimab in the US: The FARETINA Study (Jorge Rocha) 5:35 – 5:42 PM — TRUCKEE: 3.5 Years Real-World Efficacy and Safety of Faricimab in nAMD (Carlos Zeolite) 5:43 – 5:50 PM — Aflibercept 8mg in DME: Key Results from the PHOTON Extension Study (Francisco Rodriguez) 5:51 – 5:58 PM —Aflibercept 8 mg in Macular Edema Following Retinal Vein Occlusion: Week 64 Results from the QUASAR Trial (Arnaldo Bordon) 5:59 – 6:09 PM — IL-6 Rather than VEGF Plays Role in UME/NIU (Ariel Schlaen)
6:10 – 6:15 PM	Closing Remarks
6:30 – 7:00 PM	Shuttles depart for the Lake House Dinner
7:30 – 10:00 PM	Fabula Lake House Dinner Sponsored Sponsored

Bariloche · March 28–29, 2026

LATAM EYE CLINICAL TRIAL SYMPOSIUM

Quick Links

Event Info

Contact Info